Castrate-resistant Prostate Cancer

Castrate-resistant Prostate Cancer Market Outlook

The global castrate-resistant prostate cancer market is anticipated to reach approximately USD 20 billion by the end of 2035, growing at a CAGR of 8% during the forecast period from 2025 to 2035. The increasing prevalence of prostate cancer, particularly among older men, is a significant driver for this growth. Moreover, advancements in treatment methodologies and the advent of novel therapeutic agents aimed specifically at castrate-resistant prostate cancer (CRPC) have led to improved survival rates and quality of life for patients. Government initiatives geared towards cancer research, along with heightened awareness around early diagnosis and treatment, have also contributed to the market expansion. Furthermore, the rise in healthcare expenditure and better access to advanced treatment options globally are expected to bolster market dynamics.

Growth Factor of the Market

Several growth factors are propelling the castrate-resistant prostate cancer market forward. Firstly, the aging population is a notable contributor, as prostate cancer is predominantly diagnosed in older males, particularly those above 65 years. As the global demographic continues to shift toward an older population, the incidence of CRPC is expected to rise significantly. Secondly, the growing investment in oncology research has led to the development of innovative therapies that target resistant forms of prostate cancer, improving patient outcomes. Thirdly, the rise in the number of cancer treatment centers and specialized clinics has made access to advanced treatment options easier for patients. Additionally, the increasing awareness regarding prostate cancer screening and treatment methodologies is likely to increase diagnosis rates, further driving market growth. Lastly, the strategic collaborations between pharmaceutical companies and research institutions have resulted in promising clinical trials for new drugs, enhancing the therapeutic landscape for CRPC.

Key Highlights of the Market

• The castrate-resistant prostate cancer market is projected to grow at a CAGR of 8% from 2025 to 2035.
• North America holds the largest market share, driven by high healthcare expenditure and advanced medical facilities.
• Emerging therapies such as targeted therapies and immunotherapies are gaining traction among healthcare providers.
• Early diagnosis and treatment advancements are significantly improving patient outcomes.
• Government initiatives aimed at increasing awareness and screening for prostate cancer are on the rise.

By Product Type

Chemotherapy Drugs:

Chemotherapy drugs are one of the primary treatment modalities for castrate-resistant prostate cancer (CRPC). These drugs are designed to kill rapidly dividing cancer cells and are typically used when other hormonal therapies fail. Commonly used chemotherapy agents include Docetaxel and Cabazitaxel, which have shown to extend survival in metastatic CRPC patients. The increasing use of chemotherapy, particularly in advanced stages of prostate cancer, is expected to drive this segment of the market. Additionally, new formulations and combinations of chemotherapy with other therapeutic agents are being explored in clinical trials, further expanding the efficacy and application of these drugs.

Hormone Therapy Drugs:

Hormone therapy remains a cornerstone in the treatment of castrate-resistant prostate cancer, focusing on the androgen receptor pathway. Drugs such as Abiraterone Acetate and Enzalutamide help inhibit testosterone production or block its effects on cancer cells, significantly slowing disease progression. The growing recognition of the importance of hormone therapy in managing CRPC is expected to bolster this segment of the market. Furthermore, ongoing research into novel hormonal agents and combination therapies is likely to enhance treatment outcomes, driving sales growth for this category.

Immunotherapy Drugs:

Immunotherapy is an exciting and rapidly evolving segment of the castrate-resistant prostate cancer market. Treatments like Sipuleucel-T have been designed to stimulate the patient's immune system to recognize and attack cancer cells more effectively. The introduction of immune checkpoint inhibitors and other biologic therapies is further diversifying the treatment landscape for CRPC. As researchers uncover more about the tumor microenvironment and immune response, the scope for immunotherapy in managing CRPC is expected to expand significantly, attracting substantial investments and attention from pharmaceutical developers.

Targeted Therapy Drugs:

Targeted therapy drugs are tailored treatments that focus on specific genetic or molecular markers associated with castrate-resistant prostate cancer. Agents such as Radium-223 Dichloride target bone metastases specifically, offering therapeutic benefits with reduced side effects compared to traditional chemotherapy. The targeted therapy approach is increasingly gaining popularity among oncologists and patients alike, as it enhances treatment precision and efficacy. As the understanding of CRPC genetics improves, the targeted therapy segment is poised for considerable growth, fueled by ongoing research and development efforts in this domain.

Radiopharmaceuticals:

Radiopharmaceuticals are emerging as a promising treatment option for patients with advanced castrate-resistant prostate cancer, especially those with bone metastases. These therapeutic agents utilize radioactive isotopes to deliver targeted radiation therapy directly to cancer cells, minimizing damage to surrounding healthy tissue. The effectiveness of Radium-223 Dichloride as a radiopharmaceutical in prolonging survival and improving quality of life highlights their potential in CRPC treatment strategies. As the clinical evidence supporting the use of radiopharmaceuticals continues to grow, this segment is expected to witness substantial advancements and market expansion.

By Application

Hospitals:

Hospitals play a crucial role in the administration of treatments for castrate-resistant prostate cancer, providing comprehensive care that includes diagnosis, therapy, and follow-up. These institutions are equipped with advanced diagnostic tools and treatment facilities, making them the primary choice for patients. In addition, hospitals often conduct clinical trials, contributing significantly to the advancement of CRPC therapies. The demand for hospital-based care is expected to grow as the incidence of prostate cancer rises and as more individuals seek specialized treatment options for advanced disease stages.

Cancer Research Centers:

Cancer research centers are vital for driving innovation in the treatment of castrate-resistant prostate cancer. These centers focus on conducting groundbreaking research and clinical trials that lead to the development of new therapies and improved patient care standards. Their emphasis on understanding the underlying biology of CRPC and exploring novel treatment methodologies significantly contributes to advancements in the field. As collaborations between research centers and pharmaceutical companies increase, the impact of research centers on the CRPC market is likely to expand, ensuring that new and effective treatments become available for patients.

Specialty Clinics:

Specialty clinics are becoming increasingly popular among patients due to their focused approach to cancer care. These clinics often provide personalized treatment plans and have experts specializing in oncology, which can result in better patient outcomes. The growth of specialty clinics tailored specifically for prostate cancer treatment is a response to the demand for targeted and specialized care. As more patients seek alternatives to traditional hospital settings, the role of specialty clinics in the castrate-resistant prostate cancer market is expected to grow significantly, providing accessible and advanced treatment options.

Ambulatory Surgical Centers:

Ambulatory surgical centers (ASCs) offer a convenient alternative for patients requiring minimally invasive procedures related to castrate-resistant prostate cancer. These centers are designed to provide surgical care without the need for overnight hospitalization, focusing on patient convenience and cost-effectiveness. The growth of ASCs can be attributed to the increasing trend toward outpatient care and advances in surgical techniques. As more procedures are performed in outpatient settings, the contribution of ASCs to the castrate-resistant prostate cancer market is anticipated to grow, offering patients an efficient and effective treatment option.

Others:

This category encompasses various applications relevant to the castrate-resistant prostate cancer market, including home care services and telemedicine solutions. As healthcare continues to evolve and adapt to patient needs, alternative care settings are becoming increasingly important. Telemedicine, in particular, has gained traction due to its ability to provide remote consultations, follow-ups, and monitoring for patients with CRPC. The flexibility and accessibility offered by these alternatives are expected to lead to further growth in the market, catering to the diverse needs of patients facing prostate cancer.

By Distribution Channel

Hospital Pharmacies:

Hospital pharmacies serve as a critical distribution channel for various medications used in the treatment of castrate-resistant prostate cancer. These pharmacies are integral to the healthcare delivery system, ensuring that patients receive timely access to essential drugs, including chemotherapy and hormone therapy agents. The proximity of hospital pharmacies to clinical staff allows for effective communication and collaboration when managing patient treatment plans, enhancing overall care. As more hospitals adopt comprehensive cancer treatment programs, the role of hospital pharmacies in the CRPC market will continue to be vital.

Retail Pharmacies:

Retail pharmacies are increasingly becoming a significant distribution channel for castrate-resistant prostate cancer medications, especially for patients requiring ongoing therapy after hospital discharge. These pharmacies facilitate access to oral medications and maintain a close relationship with patients, providing counseling and guidance on drug usage. The rise in patient awareness and the increasing number of retail pharmacy chains offering specialized oncology services are likely to drive growth in this segment. Retail pharmacies play a crucial role in enhancing medication adherence, ensuring that patients obtain necessary treatments conveniently and reliably.

Online Pharmacies:

Online pharmacies are transforming the way patients access medications for castrate-resistant prostate cancer, offering a convenient alternative to traditional pharmacy settings. The growing trend of e-commerce, coupled with the increasing comfort level of patients with online transactions, has led to a surge in demand for online pharmacies. These platforms often provide competitive pricing and home delivery services, making it easier for patients to obtain their medications. As telemedicine and digital health solutions gain traction, the online pharmacy segment is expected to experience significant growth, catering to the evolving preferences of patients.

Others:

This category includes distribution channels that are not specifically classified under the major categories, such as specialty pharmacies and direct sales from pharmaceutical companies. Specialty pharmacies cater specifically to patients with complex, chronic diseases, including castrate-resistant prostate cancer, and focus on the distribution of high-cost medications. Direct sales from pharmaceutical companies often involve patient assistance programs that aim to provide medications to those who may not afford them through traditional channels. As the healthcare landscape evolves, these alternative distribution methods will become increasingly relevant in ensuring that patients have access to life-saving treatments.

By Ingredient Type

Abiraterone Acetate:

Abiraterone Acetate is a leading drug in the treatment of castrate-resistant prostate cancer, specifically targeting androgen synthesis. It works by inhibiting CYP17, an enzyme involved in the production of androgens, thereby reducing testosterone levels in the body. The clinical efficacy of Abiraterone in prolonging survival and delaying disease progression has made it a standard treatment for CRPC. As research continues to unveil potential combination therapies, the demand for Abiraterone is expected to remain robust, further solidifying its position in the market for prostate cancer treatment.

Enzalutamide:

Enzalutamide is another prominent drug used in the treatment of castrate-resistant prostate cancer, functioning as an androgen receptor inhibitor. It effectively prevents androgens from binding to their receptors, thus inhibiting cancer cell growth. The significant clinical trial results showcasing Enzalutamide's ability to enhance survival rates and quality of life for CRPC patients have cemented its position in oncological therapy. With ongoing research aimed at expanding its indications and potential use in earlier stages of the disease, Enzalutamide is poised for continued market growth and adoption among healthcare providers.

Docetaxel:

Docetaxel is a chemotherapy drug that has long been a cornerstone in the treatment of metastatic castrate-resistant prostate cancer. It works by disrupting the microtubule structures essential for cell division, leading to cancer cell death. Its proven efficacy in extending survival in CRPC patients makes it a frequently utilized treatment option. The utilization of Docetaxel in combination with other therapies is being actively explored, potentially expanding its applicability and reinforcing its significance within the prostate cancer treatment landscape.

Radium-223 Dichloride:

Radium-223 Dichloride is a radiopharmaceutical specifically designed for treating CRPC patients with symptomatic bone metastases. Its mechanism involves targeting bone with high-energy alpha particles, providing localized treatment while minimizing damage to surrounding healthy tissues. The ability of Radium-223 to significantly improve overall survival and quality of life for patients is driving its adoption in clinical practice. As research continues to support its efficacy and safety profile, Radium-223 is expected to play a pivotal role in advanced prostate cancer management.

Sipuleucel-T:

Sipuleucel-T is a unique immunotherapy that employs the body's immune system to fight against prostate cancer cells. It is specifically designed for patients with asymptomatic or minimally symptomatic metastatic CRPC and involves a personalized approach by utilizing the patient's own dendritic cells. The success of Sipuleucel-T in extending survival rates for certain CRPC patients has garnered significant attention and investment in immunotherapy research. As the understanding of immunological responses in prostate cancer evolves, Sipuleucel-T is set to remain a significant player in this emerging therapeutic area.

By Region

The North American region currently dominates the castrate-resistant prostate cancer market, accounting for approximately 45% of the total market share. The high prevalence of prostate cancer, extensive research and development activities, and the presence of key pharmaceutical companies contribute significantly to this dominance. Furthermore, the advanced healthcare infrastructure, coupled with high patient awareness and a strong support system for cancer research, bolsters treatment access and innovation in this region. The North American market is projected to grow at a CAGR of 7% over the forecast period, driven by continued advancements in treatment methodologies and ongoing clinical trials.

In Europe, the castrate-resistant prostate cancer market is estimated to hold a significant share, driven by the increasing incidence of prostate cancer and a growing aging population. Countries such as Germany, France, and the United Kingdom are pivotal in this growth due to their strong healthcare systems and focus on cancer research. The market in this region is projected to grow at a CAGR of approximately 6.5% during the forecast period, spurred by the rising investment in oncology and the introduction of innovative therapies aimed specifically at CRPC. Additionally, increased awareness about prostate cancer and the importance of early diagnosis are expected to enhance treatment rates across Europe.

Opportunities

The castrate-resistant prostate cancer market presents numerous opportunities for growth, particularly through the expansion of research and development initiatives. With the advent of personalized medicine, there is a growing focus on identifying specific molecular targets and tailoring therapies accordingly. This shift is likely to enable the development of more effective treatments that improve patient outcomes, presenting a lucrative avenue for pharmaceutical companies. Furthermore, the ongoing collaboration between research institutions, biotechnology firms, and healthcare providers is expected to foster innovation in treatment methodologies, leading to the emergence of new agents that specifically target resistant forms of prostate cancer.

Another significant opportunity lies in the increasing adoption of telemedicine and digital health solutions. As the demand for convenient healthcare options rises, telemedicine can significantly enhance patient engagement and adherence to treatment protocols. This approach can provide patients with remote monitoring and support, ensuring they receive timely interventions as needed. The integration of digital tools into the patient care pathway can also facilitate better communication between patients and healthcare providers, fostering a more collaborative treatment approach. As telemedicine continues to evolve, it holds the potential to revolutionize the management of castrate-resistant prostate cancer, ensuring that patients have access to essential resources and support.

Threats

The castrate-resistant prostate cancer market faces various threats, particularly concerning competition and the availability of alternative treatment options. With numerous pharmaceutical companies investing in research and development, there is an increasing number of therapies being introduced into the market. This heightened competition can lead to pricing pressures, which may impact profit margins for some companies. Furthermore, the availability of generic versions of established therapies could also create challenges for branded drug manufacturers, particularly as patients and healthcare providers increasingly seek cost-effective treatment options. As the landscape becomes more competitive, companies must continuously innovate and differentiate their offerings to maintain their market position.

Additionally, the complex nature of prostate cancer and its treatment presents an inherent challenge. Castrate-resistant prostate cancer can vary significantly from patient to patient, necessitating personalized treatment approaches that can complicate clinical decision-making. The variability in patient responses to therapy and the emergence of treatment resistance can further complicate management strategies, posing a threat to treatment efficacy. Moreover, the socio-economic factors affecting access to healthcare, particularly in underserved communities, may limit the overall market growth by hindering timely diagnoses and treatment initiation.

Competitor Outlook

• Johnson & Johnson
• Pfizer Inc.
• Novartis AG
• Astellas Pharma Inc.
• Sanofi S.A.
• Bristol-Myers Squibb Company
• Merck & Co., Inc.
• Amgen Inc.
• GSK plc
• Teva Pharmaceutical Industries Ltd.
• Exelixis, Inc.
• Clovis Oncology, Inc.
• Hikma Pharmaceuticals PLC
• Ipsen S.A.
• Ferring Pharmaceuticals Inc.

The competitive landscape of the castrate-resistant prostate cancer market is characterized by the presence of several key players who are actively involved in developing and marketing therapies for this challenging disease. Major pharmaceutical companies such as Johnson & Johnson and Pfizer Inc. lead the market with their established drug portfolios, including innovative therapies such as Abiraterone Acetate and Enzalutamide. These companies invest heavily in research and development to advance their product offerings and maintain a competitive edge. Their strong global presence and extensive distribution networks further enhance their ability to capture significant market shares and respond to evolving patient needs.

In addition to established players, several smaller biotech firms are emerging as significant competitors in the castrate-resistant prostate cancer market. Companies like Clovis Oncology and Exelixis are focusing on niche areas within CRPC treatment, developing novel therapies that target specific cancer pathways. Their agility in research and development allows them to adapt quickly to market changes and pursue innovative treatment options. Collaborations between these smaller firms and larger pharmaceutical companies are also becoming more common, enabling them to leverage resources and expedite the development of new therapies.

Furthermore, the market is witnessing a surge in partnerships and collaborations between pharmaceutical companies and academic institutions or research organizations. This trend is aimed at advancing the understanding of prostate cancer biology and facilitating the discovery of innovative treatment solutions. By pooling resources and expertise, these collaborations are likely to lead to the development of therapies that address unmet medical needs within the CRPC landscape. As the competitive landscape continues to evolve, companies must remain vigilant and proactively adapt their strategies to stay ahead in the ever-changing environment.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 GSK plc
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 Amgen Inc.
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 Ipsen S.A.
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 Novartis AG
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 Pfizer Inc.
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 Sanofi S.A.
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 Exelixis, Inc.
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 Johnson & Johnson
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 Merck & Co., Inc.
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 Astellas Pharma Inc.
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 Clovis Oncology, Inc.
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 Hikma Pharmaceuticals PLC
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 Bristol-Myers Squibb Company
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 Ferring Pharmaceuticals Inc.
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 Teva Pharmaceutical Industries Ltd.
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Castrate-resistant Prostate Cancer Market, By Application
    • 6.1.1 Hospitals
    • 6.1.2 Cancer Research Centers
    • 6.1.3 Specialty Clinics
    • 6.1.4 Ambulatory Surgical Centers
    • 6.1.5 Others
  • 6.2 Castrate-resistant Prostate Cancer Market, By Product Type
    • 6.2.1 Chemotherapy Drugs
    • 6.2.2 Hormone Therapy Drugs
    • 6.2.3 Immunotherapy Drugs
    • 6.2.4 Targeted Therapy Drugs
    • 6.2.5 Radiopharmaceuticals
  • 6.3 Castrate-resistant Prostate Cancer Market, By Ingredient Type
    • 6.3.1 Abiraterone Acetate
    • 6.3.2 Enzalutamide
    • 6.3.3 Docetaxel
    • 6.3.4 Radium-223 Dichloride
    • 6.3.5 Sipuleucel-T
  • 6.4 Castrate-resistant Prostate Cancer Market, By Distribution Channel
    • 6.4.1 Hospital Pharmacies
    • 6.4.2 Retail Pharmacies
    • 6.4.3 Online Pharmacies
    • 6.4.4 Others

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Asia Pacific - Market Analysis
    • 10.2.1 By Country
      • 10.2.1.1 India
      • 10.2.1.2 China
      • 10.2.1.3 Japan
      • 10.2.1.4 South Korea
  • 10.3 Latin America - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 Brazil
      • 10.3.1.2 Argentina
      • 10.3.1.3 Mexico
  • 10.4 North America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 USA
      • 10.4.1.2 Canada
  • 10.5 Middle East & Africa - Market Analysis
    • 10.5.1 By Country
      • 10.5.1.1 Middle East
      • 10.5.1.2 Africa
  • 10.6 Castrate-resistant Prostate Cancer Market by Region

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Castrate-resistant Prostate Cancer market is categorized based on

By Product Type

• Chemotherapy Drugs
• Hormone Therapy Drugs
• Immunotherapy Drugs
• Targeted Therapy Drugs
• Radiopharmaceuticals

By Application

• Hospitals
• Cancer Research Centers
• Specialty Clinics
• Ambulatory Surgical Centers
• Others

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Others

By Ingredient Type

• Abiraterone Acetate
• Enzalutamide
• Docetaxel
• Radium-223 Dichloride
• Sipuleucel-T

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• Johnson & Johnson
• Pfizer Inc.
• Novartis AG
• Astellas Pharma Inc.
• Sanofi S.A.
• Bristol-Myers Squibb Company
• Merck & Co., Inc.
• Amgen Inc.
• GSK plc
• Teva Pharmaceutical Industries Ltd.
• Exelixis, Inc.
• Clovis Oncology, Inc.
• Hikma Pharmaceuticals PLC
• Ipsen S.A.
• Ferring Pharmaceuticals Inc.